All In MedTech

FDA Clearance Tracker · P000025-S129

MED-EL CI System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 3, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 3, 2024

Approved

Time to decision

344 days

Received Oct 25, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P000025-S129
Device name
MED-EL CI System
Applicant
Med-El Corp.
Applicant location
Innsbruck
Received
Oct 25, 2023
Decided
Oct 3, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P000025

Device type

Device class
Class III

Every decision under product code MCM

FDA's approval statement

As written in FDA's record.

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the MED-EL Cochlear Implant (CI) System for expanding the indications for use. The expanded device indications include individuals with bilateral hearing loss who meet the following criteria:The MED-EL Cochlear Implant System is intended to evoke auditory sensations via electrical stimulation of the auditory pathways for individuals with debilitating sensorineural hearing loss who obtain limited benefit from acoustic amplification in the ear(s) to be implanted and is indicated for the following patient populations: • Individuals of eighteen (18) years of age or older with bilateral moderate to profound sensorineural hearing loss who obtain limited benefit from appropriately-fit hearing aids. These individuals typically demonstrate a low-frequency pure-tone average of greater than 40 dB HL (at 250 Hz, 500 Hz, and 1000 Hz) and thresholds not better than 65 dB HL at 3000-8000 Hz. Limited benefit from hearing aids is defined by test scores of 50% correct or less in the ear to be implanted and 60% or less in the non-implant ear on recorded tests of monosyllabic word recognition (Consonant-Nucleus-Consonant [CNC] Words).• MED-EL strongly recommends a hearing aid trial prior to implantation (if not already completed), but radiological evidence of cochlear ossification may preclude a hearing aid trial.

Source documents

Other decisions for Med-El Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.